Rheumatoid Arthritis Completed Phase 3 Trials for Sarilumab (DB11767)

Also known as: RA / Rheumatic Arthritis / Arthritis, Rheumatoid / Arthritis,Rheumatoid / Rheumatoid Arthritis (RA) / Rheumatoid Arthritis(RA) / Arthritis, Rheumatoid (RA) / Systemic rheumatoid arthritis / Arthritis rheumatoid / Rheumatoid arthritis, unspecified / R arthritis / Rh arthritis / Atrophic arthritis

IndicationStatusPhase
DBCOND0027961 (Rheumatoid Arthritis)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02293902A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)Treatment
NCT02373202A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)Treatment
NCT02121210To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)Treatment
NCT02057250To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid ArthritisTreatment
NCT01768572To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)Treatment
NCT01709578To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)Treatment